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While the human antiretroviral defense factors APOBEC3F and APOBEC3G are potent inhibitors of the replication of HIV-1 mutants
lacking a functional vif gene, the Vif protein expressed by wild-type HIV-1 blocks the function of both host cell proteins. Here, we report that
a third human protein, APOBEC3B, is able to suppress the infectivity of both Vif-deficient and wild-type HIV-1 with equal efficiency.
APOBEC3B, which shows ¨58% sequence identity to both APOBEC3F and APOBEC3G, shares the ability of these other human proteins
to bind the nucleocapsid domain of HIV-1 Gag specifically and to thereby package into progeny virion particles. However, APOBEC3B
differs from APOBEC3F and APOBEC3G in that it is unable to bind to HIV-1 Vif in co-expressing cells and is therefore efficiently packaged
into HIV-1 virions regardless of Vif expression. Unfortunately, APOBEC3B also differs from APOBEC3F and APOBEC3G in that it is not
normally expressed in the lymphoid cells that serve as targets for HIV-1 infection. These studies therefore raise the possibility that activation
of the endogenous APOBEC3B gene in primary human lymphoid cells could form a novel and effective strategy for inhibition of HIV-1
replication in vivo.
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Intrinsic immunity has recently been identified as a
significant factor in preventing retroviral infection, partic-
ularly across species barriers (Bieniasz, 2004). One impor-
tant form of intrinsic immunity is provided by the
APOBEC3 family of proteins, and particularly by human
APOBEC3G (hA3G) and APOBEC3F (hA3F), which are
able to block infection of human cells by not only Vif-
deficient mutants of human immunodeficiency virus type 10042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.06.005
Abbreviations: APOBEC, apolipoprotein B mRNA editing enzyme
catalytic polypeptide; AGM, African green monkey; HA, influenza virus
hemagglutinin; HIV, human immunodeficiency virus; MLV, murine
leukemia virus; NC, nucleocapsid; PBMC, peripheral blood mononuclear
cells; SIV, simian immunodeficiency virus.
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E-mail address: culle002@mc.duke.edu (B.R. Cullen).(HIV-1), but also by wild-type forms of African green
monkey simian immunodeficiency virus (SIVagm) and
murine leukemia virus (MLV) (Bishop et al., 2004; Bogerd
et al., 2004; Kobayashi et al., 2004; Liddament et al., 2004;
Mangeat et al., 2003; Mariani et al., 2003; Schro¨felbauer et
al., 2004; Sheehy et al., 2002; Wiegand et al., 2004; Zheng
et al., 2004). Moreover, hA3G and hA3F have also recently
been shown to block the retrotransposition of several
endogenous retrotransposons (Dutko et al., 2005; Esnault
et al., 2005).
In addition to hA3G and hA3F, the human genome also
contains genes encoding five other potential members of the
APOBEC3 protein family, all of which are found at a single
locus on chromosome 22 (Jarmuz et al., 2002). However, of
these five genes, only three, i.e. APOBEC3A (hA3A),
APOBEC3B (hA3B) and APOBEC3C (hA3C) have so far
been shown to be expressed in human cells and/or tissues
(Bishop et al., 2004; Jarmuz et al., 2002; Sheehy et al.,05) 281 – 288
Fig. 1. Human APOBEC3B inhibits Vif-deficient HIV-1. The HIV-1
proviral expression plasmid pNL-HXB-LUC-DVif (1.5 Ag) was co-trans-
fected into 293T cells along with 125 ng of one of the human APOBEC3
expression plasmids indicated, or the parental pcDNA3 plasmid (none) as a
control. Supernatant media were collected 44 h later and filtered. An aliquot
was then analyzed by ELISA for p24 Gag levels while the remainder was
used to infect naive 293T cells expressing viral receptors. No significant
differences in supernatant p24 Gag levels were observed (data not shown).
Induced luciferase levels were determined 24 h after infection. Data are
presented as a percentage of the luciferase activity observed in cells infected
with HIV-1DVif virus produced in APOBEC3-negative cells (none)
(average of 3350 light units per control sample). Error bars represent the
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has as yet not been reported to be able to inhibit the
infectivity of any retrovirus tested (Bishop et al., 2004;
Wiegand et al., 2004). In contrast, hA3C has been reported
to be a potent inhibitor of Vif-deficient forms of both
SIVagm and SIV from rhesus macaque (SIVmac), although
wild-type SIVagm and SIVmac were not affected (Yu et al.,
2004). However, hA3C has proven to be at best a weak
inhibitor of either wild-type or Vif-deficient HIV-1 (Bishop
et al., 2004; Doehle et al., 2005; Langlois et al., 2005;
Wiegand et al., 2004; Yu et al., 2004). Finally, hA3B was
reported by Bishop et al. (2004) to be able to inhibit both
wild-type and Vif-deficient HIV-1 infectivity while Yu et al.
(2004) reported that hA3B had at most a modest effect on
HIV-1 infectivity, although hA3B did potently inhibit the
infectivity of wild-type forms of both SIVagm and SIVmac.
Here, we report that hA3B is, in fact, a quite potent
inhibitor of the infectivity of both wild-type and Vif-
deficient HIV-1. Like hA3G, hA3B is specifically incorpo-
rated into virions due to an interaction with the HIV-1
nucleocapsid protein but, unlike hA3G, this incorporation is
not reduced by HIV-1 Vif expression and hA3B does not
bind to Vif in vivo. The inability of HIV-1 Vif to attenuate
the inhibition of viral infectivity induced by hA3B, while
inhibition by either hA3G or hA3F is effectively controlled,
appears to reflect the fact that hA3B, unlike hA3G or hA3F,
is not expressed at detectable levels in human lymphoid
tissues.
standard deviation observed in 3 independent experiments. The lower panel
shows a Western blot analyzing the expression of the various APOBEC
proteins in transfected cells, using an antibody specific for the carboxy-
terminal HA tag. This tag, which is present in three copies, affects the
migration of these proteins, which is slower than predicted by their
untagged size.Results
Human APOBEC3B inhibits HIV-1 infectivity and is
resistant to HIV-1 and HIV-2 Vif
Human APOBEC3 proteins can be divided into two
classes (Jarmuz et al., 2002) based on whether they are ¨42
kDa in size and contain two copies of the cytidine
deaminase active site first defined in human APOBEC1
(hAPO1), e.g.: hA3G, hA3F and hA3B, or are ¨21 kDa in
size with one copy of the active site, e.g.: hA3A and hA3C.
Interestingly, for hA3G, hA3F, hA3A and hA3C, this
subdivision also correlates with their ability to inhibit the
infectivity of Vif-deficient HIV-1. Specifically, as previ-
ously reported and reproduced in Fig. 1, hA3G and hA3F
are potent inhibitors of Vif-deficient HIV-1 infectivity while
hA3A and hA3C, as well as hAPO1, have little or no effect
(Bishop et al., 2004; Liddament et al., 2004; Sheehy et al.,
2002; Wiegand et al., 2004; Yu et al., 2004). This difference
is not due to differences in the level of expression of these
proteins in transfected cells (Fig. 1).
Human APOBEC3B also contains two copies of the
cytidine deaminase active site and shows a high degree of
sequence homology to both hA3G (57% identity) and hA3F
(59% identity). We were therefore interested in testing
whether hA3B would also inhibit Vif-deficient HIV-1. Asshown in Fig. 1, hA3B expression indeed strongly inhibited
the infectivity of HIV-1 virions produced in its presence,
although this inhibition was perhaps somewhat less severe
than noted with hA3G or hA3F. Sequence analysis of HIV-1
reverse transcripts from cells infected with HIV-1DVif virus
produced in the presence of hA3B demonstrated extensive
G to A hypermutation of the viral sense strand. Specifically,
sequencing 12,563 bp of DNA, obtained by PCR of total
DNA from infected cells using primers specific for part of
the viral env gene, revealed 272 G to A changes out of 3502
predicted G residues, i.e., an editing rate of 7.8%. In
contrast, sequencing 4795 bp of HIV-1 env gene sequence
obtained using DNA from cells infected by HIV-1DVif
produced in the absence of any exogenous APOBEC protein
revealed only 1 G to A change, a mutation rate of <0.1%.
Analysis of the sequence context of the hA3B-mediated
editing events (Table 1) showed that the edited deoxycyti-
dine residues located on the antisense strand were flanked 5V
by either a T or, less frequently, a C residue, with purines
strongly disfavored. No strong consensus sequence for
hA3B editing was noted at the 2 or +1 position, although
Fig. 2. hAPOBEC3B inhibition of HIV-1 infectivity is not relieved by HIV-
1 or HIV-2 Vif. (A) pNL-HXB-LUC-DVif (1.5 Ag) was co-transfected into
293T cells along with plasmids expressing phA3B-HA, phA3G-HA or the
parental plasmid pcDNA3 (125 ng). Additionally, 250 ng of a plasmid
encoding HIV-1 Vif, HIV-2 Vif, or a negative control plasmid (pgDVif) was
added to the transfection. Data are presented as in Fig. 1, with an average of
4240 light units observed in the controls (none). (B) 293T cells were co-
transfected with plasmids expressing hA3B-HA, hA3G-HA, or mA3-HA
and an HIV-1 Vif expression plasmid. 48 h post-transfection, cells were
lysed and an aliquot subjected to immunoprecipitation using a monoclonal
antibody specific for the HA epitope. 10% of the input lysate and 25% of
the bound fraction were then subjected to Western analysis detecting the
HA epitope (top panel) or the HIV-1 Vif protein (bottom panel).
Table 1
Consensus editing site for the hA3B protein
hA3B 3 2 1 0 +1
A 17 33 1 0 33
C 28 23 23 100 26
G 28 13 < 1 0 2
T 27 31 76 0 39
Consensus ? ? T C ?
This table presents the observed sequence context of deoxycytidine residues
edited by hA3B when hA3B was packaged into HIV-1DVif virions
produced in its presence, based on a compilation of G to A transitions
observed in the viral coding strand. A consensus sequence is presented at
the bottom, with lack of consensus indicated by a question mark.
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These data are largely consistent with data previously
reported by Bishop et al. (2004) documenting a strong
preference for a pyrimidine residue at the 1 position
relative to the edited deoxycytidine residue.
The HIV-1 and HIV-2 Vif proteins specifically rescue the
inhibition of HIV-1 infectivity induced by hA3G or hA3F
(Conticello et al., 2003; Kao et al., 2003; Liddament et al.,
2004; Mariani et al., 2003; Mehle et al., 2004; Sheehy et al.,
2002, 2003; Stopak et al., 2003; Wiegand et al., 2004; Yu et
al., 2003). To test whether either of these Vif proteins would
rescue the infectivity of HIV-1 virions produced in the
presence of hA3B, we co-transfected 293T cells with the
proviral indicator construct pNL-HXB-LUC-DVif and either
phA3B-HA or phA3G-HA, as a positive control, in the
presence or absence of plasmids expressing HIV-1 or HIV-2
Vif (Fig. 2A). While both Vif proteins effectively rescued
the infectivity of HIV-1 virions produced in the presence of
hA3G, as expected, neither protein was able to enhance the
infectivity of HIV-1 virions produced in the presence of
hA3B (Fig. 2A). This phenotype is reminiscent of African
green monkey APOBEC3G (agmA3G) or murine APO-
BEC3 (mA3), both of which inhibit the infectivity of Vif-
deficient or wild-type HIV-1 with equal efficiency (Bogerd
et al., 2004; Kobayashi et al., 2004; Mangeat et al., 2004;
Mariani et al., 2003; Schro¨felbauer et al., 2004; Simon et al.,
1998). For both of these heterologous APOBEC3 proteins,
this resistance to inactivation by HIV-1 Vif has been shown
to correlate with the inability of HIV-1 Vif to bind these
proteins in vivo (Bogerd et al., 2004; Mariani et al., 2003;
Schro¨felbauer et al., 2004).
To test whether this is also true of hA3B, we co-
expressed HIV-1 Vif with HA-tagged hA3B, hA3G (as a
positive control) or mA3 (as a negative control) in
transfected 293T cells. 48 h after transfection, the cells
were lysed and immunoprecipitated using an HA-epitope
tag specific monoclonal antibody. The resultant precipitate
was then analyzed by Western blot using a Vif-specific
rabbit antiserum. As shown in Fig. 2B, Vif efficiently co-
immunoprecipitated with hA3G but not with mA3, as
expected. hA3B also failed to detectably interact with HIV-1
Vif, thus explaining the inability of Vif to reverse theinhibition of HIV-1 infectivity induced by this human
protein (Fig. 2A).
hA3B is packaged into HIV-1 virions due to a specific
interaction with HIV-1 nucleocapsid
Analysis of hA3G function has shown that hA3G
specifically interacts with the NC domain of the HIV-1
Gag polyprotein (Alce and Popik, 2004; Cen et al., 2004;
Scha¨fer et al., 2004; Zennou et al., 2004). Moreover, this
interaction is essential for the specific incorporation of
hA3G into HIV-1 virion particles. We therefore next asked if
hA3B would also be specifically packaged into HIV-1
virions and whether this packaging, if observed, would be
affected by HIV-1 or HIV-2 Vif. As shown in Fig. 3, hA3A,
which does not inhibit HIV-1 infectivity (Fig. 1) is not
detectably incorporated into HIV-1 virions. In contrast,
hA3G is efficiently incorporated into HIV-1 virions and this
incorporation is, as predicted, prevented by HIV-1 or HIV-2
Vif (Fig. 3). This inhibition correlates with a reduction in
the level of expression of hA3G in the virus producer cells
Fig. 4. hA3B packaging into HIV-1 virions requires RNA and the
nucleocapsid region of HIV-1 Gag. (A) 293T cells were co-transfected
with HA-tagged hAPOBEC3 expression plasmids as well as with the codon
optimized HIV-1 Gag construct psynGag or a mutant version (ZWT) of this
plasmid in which the NC region has been replaced with a leucine zipper.
Producer cell lysates and virions were collected and analyzed as in Fig. 3.
(B) Analysis of in vitro binding of hA3A-HA, hA3B-HA, hA3F-HA or
hA3G-HA to the NC/p6 region of the HIV-1 Gag protein. 35S-methionine-
labeled NC/p6 was incubated with an HA affinity matrix pre-loaded with
HA-tagged APOBEC3 proteins obtained from transfected 293T cells. The
top panel shows a Western analysis of an aliquot of the 293T cell lysates,
collected using the HA-matrix, using a monoclonal antibody specific for the
HA epitope tag. The middle panel shows an aliquot of the input 35S-labeled,
in vitro translated NC/p6 prior to incubation with the HA-matrix. The
bottom panel shows the level of NC/p6 bound by each APOBEC3-HA
protein after extensive washing and elution from the HA affinity matrix. (C)
Co-immunoprecipitation of HIV-1 Gag with hA3B is dependent on RNA.
293T cells were transfected with plasmids expressing hA3B-HA, GST and/
or HIV-1 Gag-GST. The effect of RNAse A treatment on the ability of
hA3B to bind the GST or HIV-1 Gag-GST proteins present in cell lysates
was determined as previously described (Dutko et al., 2005).
Fig. 3. hA3B packaging into HIV-1 virions is not inhibited by HIV-1 or
HIV-2 Vif. 293T cells were co-transfected as in Fig. 2A, with the exception
that the Env-deficient HIV-1 proviral expression plasmid pNL4-3DVifDEnv
was substituted for pNL-HXB-Luc-DVif. 48 h later, virions were collected
by centrifugation of the supernatant media, and subjected to Western
analysis along with a lysate of the producer cells. HA epitope tagged
APOBEC3 proteins present in either the producer cell lysate or the
disrupted virions were detected using a monoclonal antibody specific for
the HA tag. A monoclonal antibody specific for p24 Gag was used to detect
HIV-1 p24 capsid protein present in the released virions and to ensure
consistent loading of samples.
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degradation (Conticello et al., 2003; Kao et al., 2003; Marin
et al., 2003; Mehle et al., 2004; Sheehy et al., 2002, 2003;
Stopak et al., 2003; Yu et al., 2003). In the case of hA3B,
readily detectable levels were again detected in progeny
virion particles. However, unlike the case with hA3G,
neither HIV-1 nor HIV-2 Vif had any effect on the level of
hA3B virion incorporation.
As noted above, hA3G incorporation into HIV-virion
particles is dependent on the NC domain of Gag. Previously,
a mutant form of HIV-1 Gag has been reported, called Gag
ZWT, in which the NC domain has been deleted and replaced
with a leucine zipper domain from the yeast GCN4 protein
(Accola et al., 2000). This substitution rescues HIV-1 virion
production although these virions are, of course, defective.
Previously, we and others have shown that the ZWT form of
HIV-1 Gag no longer supports the incorporation of the
hA3G protein into virion particles, as confirmed in Fig. 4A
(Scha¨fer et al., 2004; Zennou et al., 2004). Moreover, Gag
ZWT was also unable to incorporate the hA3B protein, thus
implying that hA3B incorporation was likely also due to a
specific interaction with NC.
To confirm that this was indeed the case, we prepared a
recombinant, 35S-methionine labeled form of the carboxy
terminal domain of HIV-1 Gag, consisting of NC linked to
the adjacent p6 protein, by in vitro translation (Scha¨fer et al.,
2004). In parallel, we expressed HA-tagged forms of hA3A,
hA3B, hA3F and hA3G at high levels in transfected 293T
cells and then collected these proteins using an HA affinity
matrix, as previously described (Scha¨fer et al., 2004). Each
loaded HA affinity matrix was then incubated with the 35S-
labeled NC/p6 protein, extensively washed and bound
proteins detected by gel electrophoresis and fluorography.
As shown in Fig. 4B, we observed readily detectable levels
of the NC/p6 protein bound to the HA affinity matrices pre-
loaded with hA3G or hA3F. In contrast, the HA affinity
matrix pre-loaded with hA3A failed to interact with NC/p6.
Finally, the matrix pre-loaded with hA3B also was able tobind the NC/p6 protein (Fig. 4B). Together, these data argue
that hA3B, like hA3G and hA3F, is able to specifically
interact with the HIV-1 NC protein and that this interaction
is critical for the specific packaging of hA3B into HIV-1
virion particles.
Fig. 5. hA3B mRNA is not detectable in primary tissues that co-express
hA3G and hA3F. (A) Weak expression of hA3B mRNA in a number of
transformed human cell culture lines. Total RNA extracted from the cell
lines indicated was subjected to RT followed by 35 cycles of PCR using
gene specific primers for either hA3B, hA3F or hA3G. Primers specific
for GADPH were added to samples for 30 rounds of PCR and were used
as a control. The right lane used an equimolar mixture of the expression
plasmids encoding hA3B, hA3F or hA3G and serves as a positive control
for PCR amplification by each APOBEC primer set, and as a negative
control for the GAPDH primers. (B) hA3B mRNA was not detected in a
range of primary human tissue samples. Top panel represents a pre-
normalized cDNA tissue panel of human lymphoid tissues. Bottom panel
samples are from a commercial human cDNA panel. Both hA3G and
hA3F mRNAwere readily detected in most of these tissue-specific mRNA
samples, as previously described (Wiegand et al., 2004). +, hA3B plasmid
DNA; Neg, no cDNA added; M, marker; PBL, peripheral blood
lymphocytes. (C) Specificity control for the hA3B primers used. hA3B
primers were tested using the hAPOBEC3 expression plasmids used in
this study.
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protein is that it requires the presence of non-specific, i.e.,
cellular RNA (Scha¨fer et al., 2004; Zennou et al., 2004). To
test whether this is also true of the HIV-1 Gag:hA3B
interaction, we co-transfected cells with a plasmid express-
ing HA-tagged hA3B and a plasmid expressing either GST
or a full-length HIV-1 Gag-GST fusion protein. After 48 h,
the transfected cells were lysed and the clarified lysate
incubated in the presence or absence of RNAse A, as
previously described (Dutko et al., 2005). After incubation,
GST, and the HIV-1 Gag-GST fusion protein, were
recovered using glutathione-sepharose beads and bound
proteins resolved by gel electrophoresis (Dutko et al., 2005).
As shown in Fig. 4C, the HIV-1 Gag-GST fusion protein
bound hA3B specifically in vivo but this interaction was
disrupted by RNAse A treatment. Therefore, specific
binding of hA3B by HIV-1 Gag is similar to hA3G binding
in that both are RNA-dependent.
hA3B is expressed at very low levels in human tissues
T cells and, indeed all human cells, can be divided into
two categories based on whether they are able to support
the replication of Vif-deficient HIV-1 (permissive cells) or
unable to do so (non-permissive cells) (Bieniasz, 2004).
Previous analysis has shown that non-permissive T cells,
such as the cell lines HUT78, H9 and CEM, as well as
primary peripheral blood mononuclear cells (PBMCs), co-
express both hA3G and hA3F (Bishop et al., 2004; Sheehy
et al., 2002; Wiegand et al., 2004). In contrast, permissive
cells, such as SupT1 and CEM-SS cells, express neither
hA3G nor hA3F. We therefore asked if the non-permissive
cell lines H9 and CEM, or the permissive cell line CEM-
SS, expressed hA3B mRNA using a previously described
semi-quantitative RT-PCR assay (Wiegand et al., 2004). As
positive controls, we included RNA derived from two
human cell lines, the chronic myelogenous leukemia cell
line K562 and the colorectal adenocarcinoma cell line
SW480, that had been previously reported to express
hA3B mRNA (Jarmuz et al., 2002). For this RT-PCR
analysis, we used previously characterized primers specific
for hA3G, hA3F or hA3B (Bishop et al., 2004; Wiegand
et al., 2004).
As shown in Fig. 5A, hA3G and hA3F mRNA was
observed at readily detectable levels in the non-permissive T
cell lines H9 and CEM, as previously reported (Bishop et
al., 2004; Wiegand et al., 2004; Sheehy et al., 2002), as well
as in the K562 and SW480 cell lines. No hA3G or hA3F
mRNAwas detected in the permissive cell line CEM-SS, as
expected. In contrast, we detected only a low level of hA3B
mRNA in SW480 cells and even less in the cell lines K562
or CEM. No hA3B mRNA was detected in H9 or CEM-SS
cells. This difference was not due to the inefficiency of the
hA3B primers used, as shown by PCR using cDNA
expression plasmids for hA3B, hA3F and hA3G (Fig. 5A,
right lane).Given the low or undetectable level of expression of hA3B
in the cell lines tested, we next asked if hA3B mRNAwould
be detectable in primary human tissues, including a range of
lymphoid tissues. Importantly, while we have previously
shown that almost all of these tissues express readily
detectable levels of hA3G and hA3F mRNA (Wiegand et
al., 2004), no hA3B mRNAwas detected in this analysis. We
therefore conclude that hA3B mRNA is either expressed in
human tissues not analyzed in this panel or is induced in
response to stimuli that have yet to be defined.Discussion
In this report, we have analyzed the ability of hA3B to
inhibit the infectivity of HIV-1 in culture. hA3B is closely
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have been shown to potently inhibit the replication of Vif-
deficient mutants of HIV-1 but that have little effect on the
replication of wild-type HIV-1 (Bishop et al., 2004; Jarmuz
et al., 2002; Sheehy et al., 2002; Wiegand et al., 2004;
Zheng et al., 2004). In contrast, we here show that hA3B is
equally effective at inhibiting both wild-type and Vif-
deficient HIV-1 (Figs. 1 and 2). While perhaps slightly less
effective than hA3G or hA3F at inhibiting Vif-deficient
HIV-1, the level of inhibition by hA3B of both wild-type
and Vif-deficient HIV-1 was still 10- to 20-fold in this
analysis (Figs. 1 and 2) and involved hypermutation of the
HIV-1 genome (Table 1). The inability of HIV-1 Vif to block
the inhibition of HIV-1 infectivity induced by hA3B (Fig.
2A) correlated with the inability of HIV-1 Vif to bind to
hA3B in vivo (Fig. 2B) and to reduce the incorporation of
hA3B into HIV-1 virions (Fig. 3). However, hA3B was
similar to hA3G in that incorporation into HIV-1 virions was
mediated by a specific, RNA-dependent interaction of hA3B
with the NC domain of the Gag polyprotein (Fig. 4).
The inability of HIV-1 Vif to counter the inhibition of
HIV-1 infectivity induced by hA3B might appear difficult to
understand, given that HIV-1 obviously replicates efficiently
in many human cell types both in vivo and in culture.
However, RT-PCR analysis demonstrated that hA3B, unlike
hA3G and hA3F, is not expressed at detectable levels in any
human tissue analyzed, including lymphoid tissues,
although low levels were detected in a small number of
cancer cell lines (Fig. 5). Therefore, HIV-1 may never
encounter significant levels of hA3B in its normal target cell
populations.
The phenotype of hA3B reported here is closely similar
to the phenotypes previously reported for mA3 and
agmA3G, both of which are effective inhibitors of wild-
type HIV-1 replication and both of which also fail to interact
with, or respond to, HIV-1 Vif (Bishop et al., 2004; Bogerd
et al., 2004; Mangeat et al., 2004; Mariani et al., 2003;
Schro¨felbauer et al., 2004). In the case of mA3 and
agmA3G, it seems reasonable to hypothesize that HIV-1
Vif has failed to evolve the ability to neutralize these
antiretroviral defense factors because they are expressed in a
heterologous, non-target species. Similarly, in the case of
hA3B, HIV-1 Vif and HIV-2 Vif have presumably failed to
evolve the ability to neutralize this human antiretroviral
defense factor because it is not expressed in the human
tissues targeted by these viruses.
In the case of agmA3G, we and others have previously
reported that the inability of agmA3G to respond to HIV-1
Vif, or to bind HIV-1 Vif in vivo, is due to a single amino
acid difference between hA3G and agmA3G at position
128, which is an aspartic acid in hA3G and a lysine in
agmA3G (Bogerd et al., 2004; Mangeat et al., 2004;
Schro¨felbauer et al., 2004). Analysis of the hA3B sequence
shows that this residue is a glutamic acid. In the case of
hA3G, the conservative substitution of aspartic acid with
glutamic acid at position 128 does not significantlycompromise the ability of HIV-1 Vif to block hA3G
function (Bogerd et al., 2004), so the residue(s) in hA3B
that block HIV-1 Vif binding must presumably be located
elsewhere. Given the close similarity of hA3G to hA3B in
sequence (57% identity, 68% similarity), it may prove
informative to map this residue(s) in detail.
Two groups have previously addressed the ability of
hA3B to inhibit HIV-1 infectivity and reached apparently
opposite conclusions. Specifically, Yu et al. (2004)
reported that hA3B does not effectively inhibit HIV-1
infectivity while Bishop et al. (2004) reported that hA3B is
able to inhibit HIV-1 infectivity in both the presence and
absence of Vif. Close inspection of the data presented in
these papers demonstrates, however, that both groups did
detect 4- to 8-fold inhibition of wild-type HIV-1 infectivity
by hA3B. Therefore, these different conclusions really
represent a difference in emphasis and these earlier data
actually agree quite closely with our results (Figs. 1 and 2)
although we observed a somewhat more striking degree of
inhibition by hA3B. The current report also extends these
earlier data by showing that hA3B fails to interact with
HIV-1 Vif (Fig. 2B) and is incorporated into HIV-1 virions
due to an RNA-dependent interaction with the Gag NC
domain (Figs. 3 and 4).
In this report, we present data arguing that hA3B mRNA
is expressed at undetectable levels in all the primary human
tissues examined and at low but detectable levels in the cell
lines CEM, K562 and SW480. These data are closely
comparable to data reported by Bishop et al. (2004), who
failed to detect any hA3B mRNA expression in activated
PBMCs or in the cell lines CEM-SS and H9 but did observe
low level expression in CEM cells. In contrast, Yu et al.
(2004) reported readily detectable levels of hA3B mRNA
expression in activated CD4+ T cells and small intestine and
detectable expression in heart and macrophages. While the
reason for the discrepancy between the data from Yu et al.
(2004), and the data reported here and previously by Bishop
et al. (2004) remains unknown, we note that we used the
same hA3B-specific primers as Bishop et al. (2004) while
Yu et al. (2004) used a distinct primer set.
The observation that wild-type HIV-1 is highly sensitive
to inhibition by mA3 and agmA3G suggests that ectopic
expression of these proteins could be used to block HIV-1
replication in vivo. Similarly, expression of hA3B in
lymphoid cells susceptible to infection by HIV-1 should
also effectively block HIV-1 replication, with the notable
difference that hA3B is a normal human gene that happens
not to be expressed in lymphoid cells. It therefore may be
possible to activate the endogenous hA3B gene in lymphoid
cells and therefore block HIV-1 replication. In the case of
beta thalassemias, attempts to activate the expression of the
otherwise silent fetal hemoglobin gene in adult cells using
agents such as hydroxyurea, 5-azacytidine or butyric acid
have been partially successful in activating fetal hemoglobin
expression in culture (Schrier and Angelucci, 2005). It
would therefore appear worthwhile to examine whether
B.P. Doehle et al. / Virology 339 (2005) 281–288 287analogous approaches might exert a similar effect on hA3B
expression in primary CD4+ T cells or macrophages in
culture and, if so, whether this resulted in a significant
inhibition in the level of HIV-1 replication.Materials and methods
Construction of molecular clones
The HIV-1 proviral expression plasmids pNL-HXB-
LUC-DVif and pNL4-3DVifDEnv have been described
(Bogerd et al., 2004; Wiegand et al., 2004), as have the
expression plasmids phA3A-HA, phA3C-HA, phA3F-HA,
phA3G-HA, phAPO1-HA, pmA3-HA, pgVif, pgVif2,
pgDVif and pK/HIVGAG-GST (Bogerd et al., 2004; Dutko
et al., 2005; Simon et al., 1998). A plasmid expressing HA-
tagged hA3B was constructed similarly by PCR amplifica-
tion from a cDNA preparation of the human cell line K562
using the following primers:
5V primer: 5V-GCGCGGTACCACCATGAATCCACA-
GATCAGAAATCCG-3V;
3V primer: 5V-GCGCCAATTGGTTTCCCTGATTCTG-
GAGAATGG-3V.
Plasmid psynGag, encoding a codon optimized HIV-1
Gag protein, and psynGag-ZWT, encoding a nucleocapsid
(NC) deletion mutant of HIV-1 Gag, have been described
elsewhere (Accola et al., 2000; Cowan et al., 2002; Scha¨fer
et al., 2004).
Cell culture and analysis
K562, CEM, CEM-SS and H9 cells were cultured in
RPMI media containing 10% fetal calf serum (FCS) while
SW480 cells were cultured in Leibovitz L-15 media
containing 10% FCS. 293T cells were cultured in DMEM
containing 10% FCS and were transfected using the calcium
phosphate method. HIV-1 infectivity assays were performed
as described previously (Bogerd et al., 2004; Wiegand et al.,
2004).
Virion packaging of APOBEC3 proteins was analyzed as
previously described (Bogerd et al., 2004; Scha¨fer et al.,
2004; Wiegand et al., 2004). Briefly, 293T cells were
transfected with either pNL4-3DVifDEnv, psynGag or
psynGag-ZWT and an APOBEC3 expression plasmid. 44 h
later, the virus containing supernatant media were collected,
filtered, and layered onto a 20% sucrose cushion. Virions
were collected by centrifugation at 35,000 rpm for 1.5 h at
4 -C in a Beckman SW41 rotor. Pellets were lysed and
analyzed by Western blot.
The level of editing of HIV-1 proviral DNA by hA3B
was analyzed as previously described (Wiegand et al.,
2004). Briefly, HIV-1DVif virus was produced in the
presence or absence of hA3B as described for the HIV-1infectivity assays (Fig. 1). Target cells were then infected
with virus containing media and 16 h after infection total
DNA was isolated using a DNeasy tissue kit (Qiagen).
Isolated DNA was DpnI treated and then used as the
template to PCR amplify part of the HIV-1 env gene.
Amplified fragments were cloned and sequenced.
Western blot analysis
Cell lysates, virion lysates and immunoprecipitates were
subjected to gel electrophoresis and then transferred to
nitrocellulose membrane. Membranes were probed with a
mouse monoclonal antibody specific for the HIV-1 capsid
protein (Chesebro et al., 1992), a mouse monoclonal
antibody specific for the HA epitope tag (Covance), or a
rabbit polyclonal antisera specific for the HIV-1 Vif protein
(Goncalves et al., 1996). Reactive proteins were detected
with Lumi-Light Western Blotting Substrate (Roche) as
previously described (Bogerd et al., 2004; Wiegand et al.,
2004).
In vitro binding assays
The 35S-methionine-labeled NC/p6 domain of the HIV-1
Gag protein was synthesized by in vitro translation using a
TNT coupled transcription/translation system, as described
previously (Scha¨fer et al., 2004). In parallel, 293T cells were
transfected with APOBEC3 protein expression plasmids and
48 h later, cultures were lysed and loaded onto an HA
affinity matrix (Covance). After binding, samples were
incubated with the in vitro translated, 35S-labeled NC
proteins, extensively washed and bound proteins detected
by SDS-PAGE and fluorography.
mRNA expression analysis
Analysis of the tissue expression pattern of human
mRNAs was performed using RT-PCR, as previously
described (Wiegand et al., 2004), using either pre-normal-
ized human multiple tissue cDNA panels (BD/Clontech) or
isolated total RNA. The primers used for specific amplifi-
cation of the hA3G, hA3F or hA3B cDNAs have been
described (Bishop et al., 2004; Bogerd et al., 2004).
Amplification reactions using the cDNA panels were
performed according to the manufacturer’s instructions.
Total RNA was isolated from a variety of cell lines using
TRIzol Reagent (Invitrogen), according to the manufactur-
er’s instructions. All RNA preparations were treated with
RQ1 RNase-free DNase (Promega) to remove any genomic
DNA contamination. 10 Ag of treated total RNA was
subjected to reverse transcription using the StrataScript First
Strand Synthesis System (Stratagene) using the provided
oligo(dT) primers. PCR was subsequently performed using
gene specific primers for 35 cycles of PCR under standard
conditions, with the exception of GAPDH, which was only
amplified for 30 cycles.
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